Nextgen Biomed Ltd (NXGN)
Nov 10, 2023 - NXGN was delisted (reason: acquired by Thoma Bravo)
23.94
+0.03 (0.13%)
Inactive · Last trade price on Nov 8, 2023

NextGen Healthcare Income Statement

Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
3.874.453.132.491.33
Research & Development
0.740.80.460.35-
Other Operating Expenses
0.26----
Operating Expenses
4.885.253.582.841.33
Operating Income
-4.88-5.25-3.58-2.84-1.33
Interest Expense
-0.02-0.03-0.06-0-
Interest & Investment Income
--0.10.150.01
Currency Exchange Gain (Loss)
-0-0.010.02-0.020.02
Other Non Operating Income (Expenses)
--7.360.690.16-
EBT Excluding Unusual Items
-4.9-12.65-2.84-2.55-1.3
Gain (Loss) on Sale of Investments
0----
Asset Writedown
--1.55-5.74--
Pretax Income
-4.9-14.2-8.58-2.55-1.3
Earnings From Continuing Operations
-4.9-14.2-8.58-2.55-1.3
Minority Interest in Earnings
0.010.010.0100
Net Income
-4.89-14.19-8.57-2.55-1.3
Net Income to Common
-4.89-14.19-8.57-2.55-1.3
Shares Outstanding (Basic)
87775
Shares Outstanding (Diluted)
87775
Shares Change (YoY)
15.90%0.53%8.67%22.66%12.16%
EPS (Basic)
-0.58-1.95-1.19-0.38-0.24
EPS (Diluted)
-0.58-1.95-1.19-0.38-0.24
Free Cash Flow
-2.16-4.44-2.75-2.66-1.55
Free Cash Flow Per Share
-0.26-0.61-0.38-0.40-0.29
EBITDA
-4.78-5.25-3.57-2.83-1.33
D&A For EBITDA
0.0900.0100
EBIT
-4.88-5.25-3.58-2.84-1.33
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q